Stock Highlights: Heat Biologics Inc (NASDAQ:HTBX); Growlife Inc (OTCBB:PHOT) And, Galena Biopharma Inc (NASDAQ:GALE)

Boston, MA 03/20/2014 (wallstreetpr) – Heat Biologics Inc (NASDAQ:HTBX) soared by more than 9% on Wednesday after it reported to have submitted a revised protocol to the FDA in relation to its Phase II trial of HS-110 drug. The company’s HS-110 drug is aimed at treating non-small cell cancer. The drug useslung-cancer cells that are genetically modified to accelerate a patient’s immune system against a broad range of lung-cancer antigens. Heat Biologics Inc (NASDAQ:HTBX) plans to begin the study in the third quarter and is looking forward to enroll 120 patients. The objective of the study will include overall survival rates.

Growlife Inc (OTCBB:PHOT) nosedived by almost 12% on Wednesday as some of the market commentators were not seemed to be impressed with the market frenzy that the company had recently caught up with. Hence, flowing in the reverse direction of the marijuana current, the stock has been tagged as an overly priced and risky one to venture in. Resultantly, the stock embraced hefty fall during the session. Earlier this month, Growlife Inc (OTCBB:PHOT) has formed a Joint Venture with Vape Holdings Inc. (VAPE) to finance research and development activities in relation to pharma grade extractions from cannabis.

It is reported that The Shuman Law Firm has opened an investigation into the claims raised against specified directors and officers of the Oregon-based biopharma company, Galena Biopharma Inc (NASDAQ:GALE). The firm’s investigation comes in light of the fresh allegations highlighted by thestreet.com about the company’s misrepresentation and failure to disclose certain facts. The leveled claims against the bio-pharma company includes its action of hiring a promoter, named The DreamTeam Group, in order to promote the company through articles. Resultantly, the share price of the company tripled in value in six months. Moreover, thestreet.com article noted that Galena Biopharma Inc(NASDAQ:GALE)’s CEO and its officers sold their stock at these times, when the company’s share value surged.  The Securities Exchange Commission is also investigating the matter.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact ir@edm.media.

Published by Steve Hackney

Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.

Recent Stories

SignUp Now For Our Featured Newsletter